Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
Referred to the House Committee on Armed Services.
Email me when HR 9547 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 9547. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill orders the Department of Defense to prepare a report on new, experimental treatments for veterans and service members whose PTSD does not respond to existing therapies. The report must focus on a 2026 Phase 1 study of whole‑mushroom psilocybin and evaluate safety, dosing, feasibility, and how the data could be used for active‑duty, reserve, veteran, and transitioning personnel. It also asks the DoD to outline legal pathways, resource needs, and continuity‑of‑care plans for any future pilot or expanded‑access programs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 9547
3 free questions a day, no accountSponsors
- Rep. Hamadeh, Abraham J. [R-AZ-8] (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 9547 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 9547 freeOr ask your AI assistant about HR 9547 directly:
Add to Claude, ChatGPT or Cursor